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Abstract
The advent of massive parallel sequencing (MPS) has revolutionized the field of human molecular genetics, including the
diagnostic study of mitochondrial (mt) DNA dysfunction. The analysis of the complete mitochondrial genome using MPS
platforms is now common and will soon outrun conventional sequencing. However, the development of a robust and
reliable protocol is rather challenging. A previous pilot study for the re-sequencing of human mtDNA revealed an uneven
coverage, affecting predominantly part of the plus strand. In an attempt to address this problem, we undertook a
comparative study of standard and modified protocols for the Ion Torrent PGM system. We could not improve strand
representation by altering the recommended shearing methodology of the standard workflow or omitting the DNA
polymerase amplification step from the library construction process. However, we were able to associate coverage bias of
the plus strand with a specific sequence motif. Additionally, we compared coverage and variant calling across technologies.
The same samples were also sequenced on a MiSeq device which showed that coverage and heteroplasmic variant calling
were much improved.
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Introduction
The human mitochondrial DNA (mtDNA) is a small circular
double stranded molecule that comprises 16569 bp and codes for
13 protein genes, 22 tRNAs and 2 rRNAs. All these are essential
elements to the correct function of the oxidative phosphorylation
(OXPHOS) system, a fundamental process of the cellular role of
mitochondria. For over 25 years, the pathogenicity of certain
alterations of the mitochondrial genome has been clearly
established in mtDNA disease. Despite the existence of mutation
hotspot genes and regions, and the occurrence of recurrent
mutations, these pathogenic aberrations are scattered over the
entire mitochondrial genome. This makes it necessary to
completely analyze this small genome to confirm or exclude
pathogenic mtDNA changes. Molecular analysis often requires
different and complementary methods, e.g. Southern blot, long
range (LR)-PCR, Denaturing Gradient Gel Electrophoresis
(DGGE), High Resolution Melting (HRM), quantitative (q)PCR
and Sanger sequencing for the detection and quantification of
mtDNA. The emergence of MPS technologies has provided the
diagnostic bench with a new and highly valuable tool for the
evaluation of human mtDNA integrity. However, these new
sequencing platforms have pitfalls, and crucial biases might be
created [1] such as the loss of coverage in regions with GC-
extreme (high or low) content, or the limited ability to analyze
homopolymeric stretches [2] [3]. As a result, heteroplasmic variant
calling might be severely complicated or even erroneous, as the
nucleotide representation can be too weak or unreliable in some of
these regions. In a recent study by Seneca et al. [4], the
mitochondrial genomes of 32 DNA samples were analyzed using
an Ion Torrent PGM system after enrichment with LR-PCR
amplification of the mtDNA. A major bias in read depth between
the positive and negative strand was seen for almost 10% of the
mitochondrial genome, despite the fact that the sequencing was
carried out at an average coverage of 6000. Moreover, in some
regions the data for the positive strand dropped severely, reaching
a critically low coverage. This difference in read depth between
both strands made it challenging to distinguish true low-level
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heteroplasmic variants from sequencing errors. Therefore, we
tried to develop an improved MPS-based protocol for the analysis
of the human mitochondrial genome. Several library preparation
methods and sequencing technologies were tested in order to
ameliorate the present sequencing protocol, and their outputs were
compared. We were also able to identify the specific nature of the
systematically undercovered nucleotide motifs. We are convinced
that our findings are of interest to all laboratories working on MPS
for the mtDNA, both in a research or clinical setting.
Materials and Methods
Ethics Statement
This study was approved by the ethics committee of the
Institutional Review Board (IRB) of the University Hospital (UZ
Brussel, Vrije Universiteit Brussel). For all control samples a
written informed consent was obtained. The informed consent
form was also reviewed and approved by the local ethics
committee of the IRB. For the patient samples, during clinical
consultation oral consent was given to study their genetic material
by any methods relevant to diagnostically confirm or rule out
mutations in their mtDNA. This procedure does not require a
written consent by the patient, and oral consent is recorded in a
protected medical patient file. This is a standard procedure that is
approved within the Center for Medical Genetics and accepted by
the ethics committee of the IRB of the hospital.
Sample collection and DNA
Six DNA samples, corresponding to three controls (samples 1, 2,
4 in [4]) and three patients (samples 9, 14, 21 in [4]), were
randomly selected from the previous sample cohort [4]. Total
DNA had been extracted from leukocytes using standard DNA
isolation techniques (Chemagen, Perkin Elmer, Zaventem, Bel-
gium). An overview of the samples and techniques used is given in
Supporting Information S1.
Long range PCR
MPS data files, obtained from a previous study, were mainly
generated by the sequencing of three overlapping LR-PCR
fragments covering the whole mitochondrial genome (all six
samples were amplified using the ‘three overlapping’ fragment
approach, two were additionally generated with a ‘single fragment’
method) [4]. However, as was demonstrated in a previous study,
one large single LR-PCR product allowed the detection of
variants, indels and large deletions simultaneously, a situation
that is advantageous due to time and cost constrains for clinical
genetic testing. For this single LR-PCR a 16.2 kb fragment [5] was
generated using the LongAmp Taq PCR kit (New England
Biolabs, Bioke, Leiden, The Netherlands). The mitochondrial
genome was amplified from 200 ng gDNA as template in a 50 mL
PCR assay according to manufacturer’s recommendations. The
PCR protocol was adapted to an initial 30 s denaturation at 94uC,
followed by 15 cycles with first a denaturation of 10 s at 92uC,
annealing at 67uC for 30 s and an extension of 10 min at 68uC.
This was followed by 18 cycles with a denaturation of 10 s at 92uC
and an extension of 10 min +20 s every cycle at 68uC. A final
extension step was performed at 68uC for 7 min. Successful PCR
amplification was assessed using 0.8% agarose gel electrophoresis,
and products were purified with AMpure beads (Analis, Cham-
pion, Belgium).
Ion Torrent PGM sequencing
Ion Torrent semi-conductor sequencing technology detects the
incorporation of each of the four nucleotides as small changes in
pH that are provoked by the release of a proton. Library and
template preparation include an amplification step. The latter is
known as an emulsion PCR which takes place in aqueous droplets
suspended in oil.
The data files of six samples, previously sequenced using the Ion
Torrent PGM assay according to the manufacturer’s instructions
[4], were regarded as benchmark material for a comparative study
of the new protocols described in the present study. We evaluated
the following modifications to the standard protocol: different
shearing methodologies and avoiding the amplification step in the
library preparation of the Ion Torrent PGM protocol. To test the
fragmentation methods, LR-PCR products were sheared using the
Covaris M220 sonicator (Life Technologies Europe, Gent,
Belgium) and the NEBNext dsDNA Fragmentase (Bioke). For
the first fragmentation method, a dilution to 100 ng in 50 mL of
LR-PCR products were subjected to sonication for 130 s with a
duty factor of 20%, a peak incident power of 50W, a temperature
of 20uC and 200 cycles per burst, to tailor the DNA molecules into
fragments with a median size of 200 bp (Ion Xpress Plus gDNA
Fragment Library Preparation, Appendix B). A standard proce-
dure was followed for the NEBNext dsDNA Fragmentase assay.
Briefly, 1 mg of PCR product was added to 2 mL 10x Fragmentase
reaction buffer and 0.2 mL of 100x BSA. This mixture was placed
on ice for 5 min prior to the addition of 2 mL of NEBNext dsDNA
Fragmentase and an incubation at 37uC for 30 min. The reaction
was stopped by adding 5 mL of 0.5 M EDTA solution to the DNA
fragments. Sheared samples were purified using AMPure beads.
The size distribution of the fragmented DNA was assessed on the
Bioanalyzer (Agilent, Diegem, Belgium), using the High Sensitivity
Assay (Agilent, Diegem, Belgium). All further downstream
manipulations were performed according to the Ion Torrent
PGM protocol’s instructions (Ion Xpress Plus gDNA Fragment
Library preparation, Life Technologies, Gent, Belgium). Briefly,
samples were end repaired, ligated with adaptors, nick repaired
and bead purified prior to amplification of size selected (E-gel
system, Life Technologies) fragments around 330 bp long.
Fragment sizes were assessed using the Bioanalyzer system and
quantified with the Qubit 2.0 fluorimeter (Life Technologies,
Gent, Belgium). Pooled libraries were used for emulsion PCR
amplification. Sequencing reactions were run on the Ion Torrent
PGM using Ion 316 version 2 chips and the Ion PGM 200
sequencing kit (Life Technologies, Gent, Belgium).
Illumina MiSeq sequencing
To obtain 350 bp fragments LR-PCR products were sheared
with the Covaris M220 sonicator (Life Technologies Europe,
Gent, Belgium) and the NEBNext dsDNA Fragmentase enzyme
(Bioke, Leiden, The Netherlands), both starting with 1 mg LR-
PCR product. Covaris sheared LR-PCR products were fragment-
ed using custom instrument specifications (TruSeq DNA PCR-
Free Sample Preparation Guide). The protocol described, before
concerning the NEBNext dsDNA Fragmentase, was the same
except for the incubation time that was adapted to 15 min to
obtain 350 bp fragments. Next, samples were further processed
using the TruSeq DNA PCR-Free Sample Preparation protocol as
instructed by the supplier (Illumina, Eindhoven, The Netherlands).
After fragmentation, end repair, adenylation, and indexed paired
end adapter ligation, samples were pooled and processed on the
MiSeq sequencer with the MiSeq Reagent Micro Kit, v2
(Illumina). Conversely, all six samples were also processed using
the Nextera XT kit (Illumina). A single Nextera tagmentation
enzymatic reaction was used where LR-PCR products were
simultaneously fragmented and tagged with adaptors. Finally, a
limited cycle PCR protocol (12 cycles) was applied, adding
MPS of Mitochondrial DNA
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simultaneously sequencing indexes (Nextera XT DNA Sample
Preparation Guide, Illumina).
Detection threshold determination for the MiSeq
The technical error rate of the MiSeq platform was determined
with the methodology used for the Ion Torrent PGM system [4].
For the latter device, which unlike PhiX for the Illumina MiSeq
lacks an endogenous control sample, a well typed pUC19 plasmid
was used. The use of the same pUC19 DNA sample also allowed a
comparison of sequencing results across platforms. One mg of
pUC19 plasmid DNA (Thermo Fisher, Erembodegem-Aalst,
Belgium) was sheared by the Covaris or NEBNext dsDNA
Fragmentase. Subsequently, samples were processed using the
TruSeq DNA PCR-Free Sample Preparation protocol, and
sequenced on the MiSeq. The error rate of the sequencing
process was computed by calculating the ratio of non-reference
versus total bases per position. Taking the average of all ratios per
position resulted in the average error rate of the pUC19 plasmid
DNA.
Data analysis
FastQ files from all datasets, generated by either the Ion
Torrent PGM or MiSeq platforms, were mapped to the
mitochondrial revised Cambridge Reference Sequence (rCRS,
NC 012920.1) using BWA-MEM (version 0.7.5) [6]. As a metric
for coverage bias, the relative coverage was used. Applying the
SAMtools software (version 0.1.18) [7] the number of reads
mapping to each reference base was counted. The mean coverage
was calculated by averaging this value across each base in the
sequence. By computing the ratio of the coverage of a given
reference base and the mean coverage of all reference bases, the
relative coverage was obtained. This was calculated for the plus
and minus strand separately, for the total coverage of both strands
together, and was presented in graphical illustrations. To visualize
the relative coverage resulting from all different protocols and
methods tested, circular plots were generated with the freeware
Circos-0.64 software [8]. The Circos plots demonstrated in this
article are restricted to sample 1, as the coverage profiles were
consistent across all samples. To compare different methodologies,
datasets were down sampled to an average coverage of 3000 using
Picard (http://picard.sourceforge.net). The average relative cov-
erage was collected for all samples processed with the same
protocol resulting in seven datasets (Ion Torrent standard, Ion
Torrent without amplification step, Ion Torrent Covaris, Ion
Torrent NEBNext dsDNA Fragmentase, TruSeq Covaris, TruSeq
NEBNext dsDNA Fragmentase and Nextera XT). For each
dataset the fraction with a relative coverage ,0.50; ,0.25; ,0.10;
,0.05 and ,0.01 was determined. To identify the nucleotide
composition of undercovered regions GC, AT along with CT, AG,
AC and GT dinucleotide motif plots were created and correlated
to the total relative coverage, as well as the relative coverage from
each strand separately. Both the incidence (in percentages) of the
dinucleotide motifs in the mtDNA molecule, and the relative
coverage were calculated in bins of 150 nucleotides and illustrated
as bias plots.
For variant calling, three different strategies were employed and
compared. First, all data were analyzed using an in-house pipeline
based on GATK. FastQ files were aligned to the rCRS using
BWA-MEM and sorted. Next, GATK realignment around indels
and recalibration was performed. The GATK Unified Genotyper
was used for variant calling, without at random down sampling of
reads to reduce coverage. Subsequently, all variants with a quality
score ,400 were filtered from the vcf data. Second, all data were
also analyzed using the CLC Genomics Workbench (version 6.0.5)
against the rCRS. Only variants with an average quality score .
25 were selected. A third and last strategy was only implemented
on the Ion Torrent data. PGM files were mapped and variants
were called using the Torrent Suite 4.2.
For each sample analyzed with the Ion Torrent PGM or MiSeq
device, the sequencing error was determined for each position of
the genome sequence, with exception of the true variants (versus
rCRS) detected in each sample. The average sequencing error and
their standard deviations were determined for these six samples.
Potential low heteroplasmic variant levels were compared to these
values and utilized as a reliable baseline (index) to reduce the false
positive rate of the data [4].
Results and Discussion
Assessment of different PGM protocols
We have recently studied the use of the Ion Torrent PGM
sequencer system in a diagnostic setting for the nucleotide analysis
of human mitochondrial genomes of patient and control samples.
The results uncovered a rather poor performance for some of the
mtDNA regions [4]. Although it is well known that the PGM
sequencing technology has problems handling homopolymeric
stretches, an additional limitation was revealed, as a major
difference in read depth between both strands was exposed for
about 10% of the mitochondrial genome regions. For these
sequences, the relative coverage of the positive strand dropped
below 0.1. These particular patterns were reproduced in replicates
of the same and between different samples, but never observed for
pUC19 plasmid samples (Figure 1A). The causes of this remained
unknown. Previous experiments had already excluded primer, LR-
PCR or sample dependence, and it was assumed that the
discrepancy originated from the enzymatic shearing step included
in the Ion Torrent assay [4]. Altering fragmentation in the original
Ion Torrent PGM assay could thus promote a change of the
coverage profile. Hence, the standard enzymatic shearing step was
omitted and substituted with an enzymatic treatment with
NEBNext dsDNA Fragmentase or with physical shearing with a
Covaris M220 sonicator device, leaving all further downstream
process steps unchanged. Nonetheless, MPS data demonstrated
that none of the altered protocols induced an equilibrated strand
representation. Neither did they show an improvement of the
under-representation of the plus strand. Uneven coverage was still
produced (Figure 1B). Both shearing methods resulted still in 7 to
7.8% of the 16.2 kb fragment to have a relative coverage of the
plus strand ,0.1. Moreover, 2% of the 16.2 kb region showed a
relative coverage of the plus strand ,0.01 (Table 1). Further
experiments, such as omission of the first PCR amplification step
in the PGM library preparation protocol were carried out and
subjected to MPS. But also this intervention did not lead to a
reduced bias (Figure 1C, Table 1). By exchanging the Platinum
Taq DNA polymerase for Kapa HiFi in the nick translation and
amplification step during library preparation, Quail et al. [9] had
demonstrated a reduced bias in PGM data. Therefore, it was
proposed that the DNA amplification treatment during the library
preparation and/or the emulsion PCR mediated a bias interfering
with all further analysis of the mitochondrial genome. In order to
further characterize the underlying mechanisms of poor PGM
results across parts of the mitochondrial genome, the depth of the
relative coverage seen at each position was tabulated for both
strands separately. Hence, a possible association with its nucleotide
composition was investigated systematically. In-house Perl scripts
were used to calculate the content of GC or AT rich motifs, as well
as any other dinucleotide rich combination. This analysis did not
disclose any relationship between GC or AT rich regions and poor
MPS of Mitochondrial DNA
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strand representation (Figure 2). The findings of Quail et al. [9]
about very low coverage from GC or AT rich motifs for
P.falciparum were not confirmed by the analysis of mtDNA. In
contrast, reduced coverage was detected for AC and CT rich
motifs. Particularly, coverage of the plus strand was negatively
influenced by these two motifs. Moreover, the relative coverage of
the plus strand dropped almost to zero for 80% (and more) AC
rich motifs (Figure 2). The sequencing bias is seen for a high AC-
content (range 70–80%) which corresponds to the figures of 80%
and more for the GC and AT motifs presented by Ross et al. [1].
It is already known for a long time that the nucleotide composition
of both mtDNA strands is different. The plus strand or light strand
is C-rich, while the minus strand or heavy strand is G-rich. The
rCRS is based on the L-strand and corresponds to the
underrepresented plus strand in our sequencing results. The
analyses were also performed for the pUC19 plasmid DNA. As
expected, no correlation between its nucleotide composition and
coverage data was observed (Supporting Information S2). We
therefore hypothesize that the troughs generated by the Ion
Torrent PGM system rather originate from the proliferation of the
sheared mtDNA sequences and not from the fragmentation
method per se. In fact, it might be inherent to the combination of
the DNA polymerases used in the PCR amplification steps
included in the standard protocols, and the nature of the
mitochondrial genome sequence.
Comparison PGM-MiSeq
We proceeded to study mitochondrial genome resequencing on
a MiSeq platform, using two different strategies. The results of the
PCR amplification free protocol of TruSeq were compared with
those of the Nextera XT kit, a method including one PCR
amplification step in the library preparation step. Experiments
were carried out according to the manufacturer’s instructions. The
average read depth for the different datasets generated with the
MiSeq were 3723, 4701 and 19418 for the TruSeq Covaris,
TruSeq NEBNext dsDNA Fragmentase and the Nextera XT
methods, respectively. The reads generated by MiSeq (paired end
reads), had a 150 bp fixed length, while reads generated by Ion
Torrent PGM showed a variable single-end read length with an
average of 145 bp. To compare different methodologies, datasets
were down sampled to an average coverage of 3000. Relative
coverage analysis showed a major improvement in strand
equilibration for the TruSeq data. Data from the TruSeq sheared
with the Covaris protocol, and the TruSeq enzymatically digested
with NEBNext dsDNA Fragmentase achieved an impressive
relative coverage, with few areas (only 1.6% and 1.6%,
respectively) of the plus strand ,0.5. The Nextera XT data did
not show strand bias as seen with the PGM data. However, a
general unevenness of coverage of both strands was seen. Indeed,
regions of both strands (9.2% of the plus strand and 9.6% of min
strand) showed a relative coverage ,0.5. (Figure 1D, Table 1)
which were associated with CT rich motifs. Unlike for the PGM,
where mainly the positive strand was involved, both strands were
affected, however not as severe as for the Ion Torrent data
(Figure 2).
Detection limit of the MiSeq
The detection threshold for the identification of base variants
was set on 5% for the Ion Torrent chemistry. This value was based
on the determination of the sequencing error and the sensitivity
and specificity experiments previously performed [4]. To set the
detection threshold for the MiSeq, the same pUC19 plasmid DNA
sample was sheared with two different methods, once using the
Covaris M220 sonicator and secondly using the NEBNext dsDNA
Fragmentase. Both differentially sheared samples were sequenced
on the MiSeq following TruSeq PCR free library preparation and
a 100% coverage was obtained with an average read depth of 30
440 and 30 966 respectively. Similar average sequencing error
results were obtained with 0.27% and 0.19% for the Covaris
sheared sample and the enzymatic sheared sample respectively.
These values are in concordance with the error rate obtained by
the PhiX, which presented with an error rate of 0.35%. These
error rates in turn correspond to previously reported data for the
MiSeq platform [9]. By applying these results to determine the
variant threshold for the mitochondrial resequencing, a detection
threshold level of 2% is possible. However as the PGM data were
previously investigated with a detection threshold of 5%, these
settings were also used for the MiSeq data.
Variant calling
Last, we assessed variant detection in all samples using the data
panel of nucleotide alterations reflecting the Sanger sequencing
previously performed. The majority of these variants were
identified on both platforms (Table 2; Supporting Information
S3). Results were collected for a PGM, TruSeq or Nextera XT
dataset. Two variant calling pipelines, an in-house pipeline based
on GATK and the Quality-based variant detection method (CLC
Genomics Workbench) were applied to MiSeq datasets, and
subsequently compared to the results of our previous study. The
TS4.2 was only used with the PGM data. The first pipeline
resulted in 99.5% of the variants detected in the TruSeq and
Nextera XT dataset, while the PGM dataset showed a 92.4%
concordance with the Sanger sequencing results. The CLC
Genomics Workbench pipeline requires the variant to be present
on both strands. 93.4%, 97.7% and 97.2% of the Sanger
sequencing variants were called in the TruSeq Covaris, TruSeq
NEBNext dsDNA Fragmentase and the Nextera XT dataset,
respectively. Applying these terms to the PGM data resulted in
84.7% concordance with Sanger sequencing. However, omitting
the strand parameter identified 95.2% of the variants for PGM
data. These figures demonstrated clearly the effect of strand bias
on variant calling for the PGM data. Indeed, 67 out of 98 false
negative results were present on one strand only. An additional
analysis with the TS4.2 software identified 96.6% of the variants.
Three positions, m.294T.C, m.16183A.C and the polymorphic
302_316 region, presented as false negative results in the PGM
data sets. An additional false negative variant, at position
m.5899_5900insC escaped variant calling. All of these variants
are situated near a homopolymeric stretch and, with the exception
of m.5899_5900insC, are also located in regions with significant
AC contents and its associated strand bias (relative coverage of the
plus strand ,0.2). It must be pointed out that, despite the well
documented shortcoming in homopolymer calling, the propriety
software is clearly well fitted for the PGM needs in variant calling.
Comparing the various algorithms applied in this present and the
previous study, the TS4.2 software was noticeably the better
performer. Compared to the former TS3.6 version, a remarkable
improvement was noticed for the false positive rate. Reanalyzing
all PGM samples with the TS4.2 release showed a reduction in
false positives from 13,4% to 8,9%, with a detection threshold level
of 5%. The highest sensitivity for the MiSeq results (TruSeq and
Nextera XT data) was obtained by our in-house pipeline based on
GATK. Indeed, the only false negative result for these data was
one specific variation in the polymorphic 302_316 region in
sample 21. Two single nucleotide insertions were detected in this
region with Sanger sequencing (m.309_310insC and
m.315_316insC), but MiSeq identified them incorrectly as a
heteroplasmic sequence mixture of molecules with an insertion of
MPS of Mitochondrial DNA
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Figure 1. Genome Coverage plots. Representation of the MPS relative coverage of both strands (rc+: relative coverage of the plus strand, rc-:
relative coverage of the negative strand) of the pUC19 plasmid, or mtDNA molecules obtained from the Ion Torrent PGM or MiSeq sequencing
system. The outer circle symbolizes the pUC19 (A) or mtDNA (B, C, D) gene structure, respectively. 1A: Use of the Ion Torrent PGM standard protocol
on the pUC19 plasmid. 1B: Use of three different fragmentation methods in combination with the Ion Torrent sequencing protocol on the mtDNA:
Ion Shear Plus Reagents (enzymatic), NEBNext dsDNA Fragmentase (enzymatic) and Covaris (physical). 1C: Use of an Ion Torrent PGM protocol
without PCR amplification in the library construction on the mtDNA. 1D: LR-PCR products of the mtDNA were Covaris (physical) or NEBNext dsDNA
Fragmentase (enzymatic) sheared, followed by a TruSeq DNA PCR free protocol on a MiSeq instrument. The same six samples were processed with a
Nextera XT kit (enzymatic shearing and PCR amplification in library preparation) prior to MiSeq analysis.
doi:10.1371/journal.pone.0112950.g001
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two or four C’s at position 309. Analysis of the Ion Torrent PGM
data previously had revealed four variants (m.7989T.C,
m.9769T.C, m.10866T.C, m.12071T.C) hitherto not identi-
fied by Sanger sequencing. These same variants were identified by
the Illumina system with analogous allele frequencies (Table 3). In
this project, a detection threshold of 5% was used for all data
analysis. However, it must be pointed out that a more stringent
detection threshold of 2% is possible for both the PGM and MiSeq
data. From a diagnostic perspective these low detection limits are
not always relevant. Most pathogenic mutations have a disease
threshold well .60%. Nonetheless, in the context of genetic
counseling of asymptomatic female relatives for family planning,
low detection limits might be indicated. Adjusting the detection
limit to 2% in our sample cohort identified two additional
heteroplasmic variants on the MiSeq platform. A novel hetero-
plasmic variant m.8207C.T (p.(Pro208Ser)) in theMT-CO2 gene
was revealed in the mtDNA of leukocytes of patient 9. Another
heteroplasmic variant, m.5609T.C, was identified in leukocytes
of patient 14 in the MT-TA gene. Both allele frequencies, 2% and
4% respectively, were below the applied detection limit of the
PGM sequencer. Both nucleotide variants, however, were
acknowledged by the PGM data as well, as was indicated by
review of the BAM files in IGV and reanalysis of the data using a
detection threshold of 0.8% (corresponding to the sequencing
error rate of the PGM device). It must be pointed out that,
although the accuracy of low level heteroplasmy determination is
heavily dependent on the depth of coverage, it is also defined by
the sequencing error of the system. The latter being related to
PCR, platform technologies, and the various algorithms imple-
mented at the different steps of data processing.
Conclusion
MPS analysis is a powerful tool able to simultaneously detect
and quantify sequencing variants. However, diagnostic settings
have high demands regarding accuracy of test results. A high
sensitivity is crucial to avoid a misdiagnosis, while a low false
positive rate is necessary to minimize additional Sanger sequenc-
ing work for confirmation of pathogenic discoveries. Our current
findings have illustrated that MPS protocols demand a thorough
evaluation of their data, and validation of the result files before a
possible implementation as a diagnostic test should be considered.
In many laboratories MPS analysis is now part of daily diagnostic
work. Selecting an appropriate methodology for MPS projects
envisioned deserves the necessary attention. Assessment of the
nucleotide content of DNA samples to be analyzed proved here to
be an essential parameter, among others, for evaluation of the
performance of a sequencing methodology or technology. In our
hands, the current Ion Torrent PGM standard assay, even with
modifications, suffered from lack of coverage consistency of the L-
strand of the human mitochondrial genome, making an evaluation
of heteroplasmy in these underrepresented regions cumbersome.
Comparison of the PGM and MiSeq Nextera XT data results with
the MiSeq PCR free sequencing method suggest that coverage
bias might be generated by the enzymes involved in the
amplification rounds of the MPS processes. Indeed, the Nextera
XT method, which included a PCR amplification step, produced
also more variation in coverage than the samples processed with
Figure 2. Nucleotide GC, AC and CT bias plots for the human mtDNA. The relative coverage as seen in this illustration is based on the
average of the relative coverage of the six samples processed with the different protocols: Covaris shearing followed by the Ion Torrent protocol,
Covaris shearing followed by the TruSeq procedure and the Nextera XT method. The average relative coverage was calculated for the total relative
coverage and for both strand separately.
doi:10.1371/journal.pone.0112950.g002
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the TruSeq DNA PCR-Free Sample Preparation protocol.
Nextera XT certainly reduced, but did not resolve the coverage
inconsistency. Further modifications, such as the use of another
DNA polymerase in both amplification steps of the standard PGM
workflow (one in the library preparation, and another in the
emulsion PCR) may lead to further improvements. However, this
might be a complex process and beyond the time management
and financial scope of this project. Consequently, at this very
moment the TruSeq DNA PCR-Free Sample Preparation
protocol on the MiSeq system might be the most appropriate
technology to address low copy number mtDNA heteroplasmy
adequately.
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